Loxo Oncology Inc (LOXO) Holdings Lifted by Lisanti Capital Growth LLC

Lisanti Capital Growth LLC boosted its stake in shares of Loxo Oncology Inc (NASDAQ:LOXO) by 49.7% in the 3rd quarter, HoldingsChannel reports. The fund owned 12,545 shares of the biopharmaceutical company’s stock after purchasing an additional 4,165 shares during the quarter. Lisanti Capital Growth LLC’s holdings in Loxo Oncology were worth $2,143,000 at the end of the most recent reporting period.

Other institutional investors also recently added to or reduced their stakes in the company. Fortaleza Asset Management Inc. acquired a new position in Loxo Oncology during the second quarter worth $110,000. First Mercantile Trust Co. acquired a new position in Loxo Oncology during the second quarter worth $122,000. Douglass Winthrop Advisors LLC acquired a new position in Loxo Oncology during the second quarter worth $204,000. Zeke Capital Advisors LLC acquired a new position in Loxo Oncology during the second quarter worth $208,000. Finally, Commonwealth Equity Services LLC acquired a new position in Loxo Oncology during the second quarter worth $209,000. Hedge funds and other institutional investors own 97.77% of the company’s stock.

Several research firms have issued reports on LOXO. Zacks Investment Research lowered Loxo Oncology from a “hold” rating to a “sell” rating in a research note on Wednesday, October 17th. BidaskClub lowered Loxo Oncology from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, October 9th. Cann reiterated an “average” rating and set a $202.00 price objective (up from $122.00) on shares of Loxo Oncology in a research note on Thursday, July 12th. Piper Jaffray Companies set a $200.00 price objective on Loxo Oncology and gave the stock a “buy” rating in a research note on Sunday, October 7th. Finally, Cowen reiterated a “buy” rating on shares of Loxo Oncology in a research note on Monday, October 22nd. One investment analyst has rated the stock with a sell rating, two have given a hold rating, fourteen have given a buy rating and one has given a strong buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $188.75.

In related news, insider Naarden Jacob Van sold 10,000 shares of the firm’s stock in a transaction dated Tuesday, August 14th. The stock was sold at an average price of $159.34, for a total value of $1,593,400.00. Following the transaction, the insider now owns 19,200 shares in the company, valued at $3,059,328. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Joshua H. Bilenker sold 20,000 shares of the firm’s stock in a transaction dated Tuesday, August 14th. The shares were sold at an average price of $159.41, for a total value of $3,188,200.00. Following the completion of the transaction, the chief executive officer now owns 145,407 shares in the company, valued at approximately $23,179,329.87. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 102,500 shares of company stock valued at $16,798,550. 17.10% of the stock is currently owned by corporate insiders.

Shares of NASDAQ:LOXO opened at $173.83 on Friday. Loxo Oncology Inc has a twelve month low of $71.45 and a twelve month high of $208.95. The firm has a market capitalization of $5.21 billion, a PE ratio of -32.74 and a beta of 2.26.

Loxo Oncology (NASDAQ:LOXO) last announced its earnings results on Thursday, November 8th. The biopharmaceutical company reported ($0.89) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.65) by ($0.24). The firm had revenue of $42.47 million during the quarter, compared to the consensus estimate of $38.55 million. During the same period in the previous year, the business posted ($2.45) EPS. Sell-side analysts predict that Loxo Oncology Inc will post -2.52 EPS for the current year.

WARNING: This report was first posted by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this report on another website, it was copied illegally and reposted in violation of US & international copyright and trademark law. The original version of this report can be accessed at https://sportsperspectives.com/2018/11/09/loxo-oncology-inc-loxo-holdings-lifted-by-lisanti-capital-growth-llc.html.

Loxo Oncology Company Profile

Loxo Oncology, Inc, a biopharmaceutical company, develops and sells medicines for patients with genetically defined cancers in the United States. Its lead product candidate comprises larotrectinib, an oral selective inhibitor of tropomyosin receptor kinase (TRK), which is in adult Phase 1 trial, a pediatric Phase 1/2 trial, and an adult/adolescent Phase 2 trial for the treatment of patients with tumor types, such as lung, head and neck, melanoma, colorectal, sarcoma, and breast cancer.

Read More: Discount Rate

Want to see what other hedge funds are holding LOXO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Loxo Oncology Inc (NASDAQ:LOXO).

Institutional Ownership by Quarter for Loxo Oncology (NASDAQ:LOXO)

Receive News & Ratings for Loxo Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Loxo Oncology and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply